Fundraising Fox
Immunomic Therapeutics
Rockville, US · Founded 2005 · Delaware corporation · 20 employees on LinkedIn · 2 known investors
Find your way into Immunomic Therapeutics
Sign up to see every warm intro you have to Immunomic Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Immunomic Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Immunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
Founders & leadership
Immunomic Therapeutics was founded in 2005 by William G Hearl.
WG
William G HearlFounder · President & CEO2006–2023William G Hearl founded Immunomic Therapeutics and serves as CEO, bringing expertise in immunology and molecular biology; he led the company through early development and negotiated a major licensing agreement with Astellas Pharma.
BC
Bernard C RudnickChief Financial Officer
BM
Bruce MacklerVice President and Director
WI
Winston I LoweChief Legal Officer and Secretary of the Board of Directors
LS
Lisa SalleyChief Operations Officer/Heritage Solutions Group2005–2013She has held senior operations and strategy roles at multiple Fortune 500 companies including GE, Dow, DuPont, and Underwriters' Laboratories, with 16+ years at GE, and holds Six Sigma certification.
Board
YG
Yang Gon JinBoard director
SP
Steve ParkBoard director
KA
Ki-Hong AhnBoard director
RA
Robert AhlgrenBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$100M disclosed across 7 rounds · 2011–2025
▶$6.5MraisedJun 2025 · 1 investors · BiotechnologyRule 506(b)
▶$6.5MraisedJun 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Yang Gon JinDirector
- Steve ParkDirector
- Robert AhlgrenDirector
- Dong-Gun KimExecutive Officer, Director
- James WishartDirector
- Ki-Hong AhnDirector
- Matthew ChangDirector
- Offering amount
- $16M
- Amount sold
- $6.5M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedApr 2024 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedApr 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James WishartDirector
- Dong-Gun KimExecutive Officer, Director
- C. ERIC WINZERExecutive Officer
- Robert AhlgrenDirector
- Steve ParkDirector
- Ki-Hong AhnDirector
- Matthew ChangDirector
- Michael LackDirector
- Ronald ThiboutotDirector
- Yang Gon JinDirector
- Offering amount
- $20.9M
- Amount sold
- $3M
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$77.7MraisedJan 2021 · 6 investors · BiotechnologyRule 506(b)
▶$77.7MraisedJan 2021 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- WILLIAM G. HEARLExecutive Officer, Director
- C. ERIC WINZERExecutive Officer, Director
- MICHAEL D. LACKDirector
- JAMES W. WISHARTDirector
- ALEX S KIMDirector
- YANG-GON JINDirector
- HYUK JOO JEEDirector
- ARLO MCGINNDirector
- RONALD P. THIBOUTOTDirector
- Offering amount
- $77.7M
- Amount sold
- $77.7M
- Sales commissions
- $3.1M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$314.5KraisedAug 2018 · 1 investors · BiotechnologyRule 506(b)
▶$314.5KraisedAug 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- MICHAEL D. LACKDirector
- WILLIAM G. HEARLExecutive Officer, Director
- WILLIAM BARRY MCDONALDDirector
- C. ERIC WINZERExecutive Officer, Director
- JAMES W. WISHARTDirector
- RONALD P. THIBOUTOTDirector
- Offering amount
- $314.5K
- Amount sold
- $314.5K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.6MraisedMar 2017 · 47 investors · BiotechnologyRule 506(b)
▶$4.6MraisedMar 2017 · 47 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- WILLIAM G. HEARLExecutive Officer, Director
- JAMES W. WISHARTDirector
- RONALD P. THIBOUTOTDirector
- WILLIAM BARRY MCDONALDDirector
- C. ERIC WINZERExecutive Officer, Director
- MICHAEL D. LACKDirector
- Offering amount
- $10M
- Amount sold
- $4.6M
- Minimum investment
- $25K
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.8MraisedOct 2014 · 56 investors · BiotechnologyRule 506(b)
▶$6.8MraisedOct 2014 · 56 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William Barry McDonaldDirector
- Teri Jones HeilandExecutive Officer
- Bruce F. MacklerExecutive Officer, Director
- Ronald ThiboutotDirector
- James WishartExecutive Officer, Director
- William G HearlExecutive Officer, Director, Promoter
- Michael D. LackDirector
- Bernard C. RudnickExecutive Officer, Director
- Offering amount
- $8.8M
- Amount sold
- $6.8M
- Minimum investment
- $10K
- Sales commissions
- $276K
- Proceeds to insiders
- $500K
- Placement agents
- Newport Coast Securities Inc.
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedMar 2012 · 7 investors · BiotechnologyRule 506(b)
▶$1.1MraisedMar 2012 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William G HearlExecutive Officer, Director, Promoter
- Bernard C RudnickExecutive Officer
- William Barry McDonaldDirector
- Teri HeilandExecutive Officer
- Bruce MacklerExecutive Officer, Director
- Ronald ThiboutotDirector
- Winston I LoweExecutive Officer
- James WishartDirector
- Lisa SalleyExecutive Officer
- Offering amount
- $2M
- Amount sold
- $1.1M
- Minimum investment
- $50K
- First sale
- Aug 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Companies working in the same space as Immunomic Therapeutics.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $308K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $334K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Immunomic Therapeutics do?
- Immunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
- Who founded Immunomic Therapeutics?
- Immunomic Therapeutics was founded by William G Hearl in 2005.
- Who are Immunomic Therapeutics's investors?
- Immunomic Therapeutics's investors include Keiretsu Forum, Life Sciences Greenhouse Investments.
- How much funding has Immunomic Therapeutics raised?
- Immunomic Therapeutics has disclosed $100M raised across 7 rounds.
- Where is Immunomic Therapeutics headquartered?
- Immunomic Therapeutics is headquartered in Rockville, US.